We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Bioabsorbable Vascular Plug Seals Arteriotomies

By HospiMedica International staff writers
Posted on 13 Aug 2014
A novel vascular closure device (VCD) provides a safe and predictable means for achieving immediate hemostasis following percutaneous femoral procedures.

The velox CD VCD is made from a proprietary AZ31 magnesium alloy, and is designed to absorb rapidly following a percutaneous transluminal coronary angioplasty (PTCA) procedure. More...
The implant portion of the closure device consists of three bioabsorbable components: an intraluminal footplate, an extraluminal plug, and a wire that holds them together. The three components work in concert to mechanically seal the arteriotomy. While the implant's intraluminal portion dissolves within just 24 hours, the remainder is completely resorbed within two weeks.

The device is positioned using the PTCA guidewire for correct orientation; the guidewire is then removed. The easy-to-use, single-use implant is indicated for the closing of arteriotomies ranging in size from 5F to 8F, providing surgeons with a closure option that seals the vessel wall, thus avoiding the need for time-consuming manual compression and allowing for shorter patient time-to-ambulation. The single size velox CD is a product of Transluminal Technologies (Syracuse, NY, USA), and has received the European Community CE marking of approval.

“Velox CD is a true next generation vascular closure device that addresses the shortcomings of extant products with vastly improved implant delivery and bioabsorption technologies,” said Stephen Green, co-founder and president of Transluminal Technologies. “Transluminal will continue its commitment to innovation in interventional devices and improved patient outcomes.”

“Velox CD is the world's first metal-based bioabsorbable closure device that is simple to use and highly predictable for femoral access site hemostasis,” added Shing-Chiu Wong, MD, director of the cardiac catheterization laboratories at the New York Presbyterian - Weill Cornell Medical Center (New York, NY, USA), and a leading clinical participant in the velox CD clinical studies. “This innovation should prove to be a significant enhancement to the existing offerings.”

Related Links:

Transluminal Technologies
Animated Velox CD Operation



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.